Johnson & Johnson UPTRAVI — Percent Change (as a percent) increased by 1675.0% to 7.1% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 297.2%, from -3.6% to 7.1%. Over 2 years (FY 2022 to FY 2025), UPTRAVI — Percent Change (as a percent) shows a downward trend with a -15.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage indicates sales growth, while a negative percentage indicates a contraction in revenue, helping to identify trends in product maturity or market saturation.
This metric measures the period-over-period percentage growth or decline in net sales for the UPTRAVI product line. It p...
Comparable to year-over-year or sequential growth rate metrics reported for individual pharmaceutical products by industry peers.
jnj_segment_uptravi_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 11% | 19% | 6.5% | 4.9% | 7.7% | 0.6% | 11.4% | 21.8% | 20.7% | 1.7% | 29.2% | 6.6% | 14.2% | -3.6% | 11.7% | 5.6% | 0.4% | 7.1% |
| QoQ Change | — | +72.7% | -65.8% | -24.6% | +57.1% | -92.2% | >999% | +91.2% | -5.0% | -91.8% | >999% | -77.4% | +115.2% | -125.4% | +425.0% | -52.1% | -92.9% | >999% |
| YoY Change | — | — | — | -55.5% | -59.5% | — | +75.4% | +344.9% | +168.8% | +183.3% | +156.1% | -69.7% | -31.4% | -112.3% | +77.3% | -60.6% | — | +297.2% |